Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized switch study of two nevirapine-based HAART dosing strategies in virologically suppressed HIV-1 patients
2006-002582-39Phase 3Completed
- Sponsor
- Fondazione Nadir
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nevirapine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Fondazione Nadir. Primary endpoint: Proportion of patients with plasma HIV viremia below 50 copies/mL at 12 months. Started Aug 2006; status: completed.
02
Drugs
nevirapine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-002582-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002582-39.